Heart Disease Journals

Cardiology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Juliard JM – The rational use of these stents requires choosing lesions at high–risk for restenosis (long lesions on small vessels, for example) in patients who can be monitored for at least one year and a dual antiplatelet therapy, which sudden discontinuation of which is a strong and independent risk factor for acute stent thrombosis with sometimes fatal consequences. These are prerequisite conditions for optimizing both the risk/benefit and cost/benefit ratios of DES. The development of full biodegradable DES stents and more effective and reproducible antiplatelet therapy is advancing to make these procedures even safer and more effective.

Related Articles

C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation
Circulation, 11/04/09    Relevance Score: 68%

Intravascular Ultrasound Assessment of the Incidence and Predictors of Edge Dissections After Drug-Eluting Stent Implantation
JACC - Journal of the American College of Cardiology: Cardiovascular Interventions, 10/23/09    Relevance Score: 68%

Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)
The American Journal of Cardiology, 11/09/09    Relevance Score: 67%

Degradable and drug-eluting stents: Mixed results
Urology Times, 11/04/09    Relevance Score: 67%

Sirolimus-eluting stent placement for refractory renal artery in-stent restenosis: sustained patency and clinical benefit at 24 months
Vascular Medicine, 10/15/09    Relevance Score: 67%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address